1.Effects of cDDP resistance on proliferation, apoptosis, migration and an-giogenesis of esophageal cancer cells
Chaohui LI ; Benhong REN ; Xuejiao SUN ; Junting KOU ; Chun HE ; Xiaoxia WANG
Chinese Journal of Pathophysiology 2017;33(1):1-6
AIM:To investigate the effect of cis-dichlorodiamine platinun ( cDDP) resistance on proliferation , apoptosis, migration and angiogenesis of esophageal cancer cell line KYSE 150.METHODS:Using the method of increa-sing concentration of cDDP in culture for 10 months, the human esophageal carcinoma cDDP-resistant cell line named KYSE150/cDDP was established successfully .The drug sensitivity was measured by MTT assay .The changes of the biolog-ical behaviors between the parental cell line and resistant cell line were determined by morphological observation assay , MTT assay, colony formation assay , DAPI staining, wound healing assay and tube formation experiment .RESULTS: No significant morphological difference between KYSE 150 cells and KYSE150/cDDP cells was observed .Compared with KYSE150 cells, the drug resistance index of KYSE150/cDDP cells was 6.35, and the viability of KYSE150/cDDP cells was decreased.The colony formation rate of KYSE150/cDDP cells was (15.00 ±3.05)%, while the colony formation rate of KYSE150 cells was (86.70 ±6.57)%.The apoptotic rate of KYSE150/cDDP cells was (0.63 ±0.09)%, and that of KYSE150 cells was (8.46 ±1.33)%.Compared with KYSE150 cells, KYSE150/cDDP cells showed a stronger healing ability of scratch, and the migration rate was higher than that of KYSE 150 cells.The results of tube formation experiment showed that the vessel number in KYSE150/cDDP group was 76.20 ±3.18, while the vessel number in KYSE150 group was 50.60 ±1.33.The protein expression of MMP-2 and VEGFR2 in KYSE150/cDDP cells was higher than that in KYSE150 cells.CONCLUSION: KYSE150/cDDP cells present drug-resistant phenotype and show a slow growth rate . The ability of apoptosis is decreased , and the abilities of cell migration and angiogenesis are increased .This may be an im-portant reason for the failure of clinical chemotherapy for esophageal cancer .
2.Odanacatib inhibits relapse of orthodontic tooth movement: an in vivo micro-CT analysis
Xiaoxia WEI ; Yuzhen ZOU ; Zhengwei KOU
Acta Universitatis Medicinalis Anhui 2017;52(12):1887-1889
To evaluated the inhibition effect of local injection of odanacatib on orthodontic relapse.Thirty rats were randomly divided into 2 groups(n =15).The maxillary right first molars of all animals were subjected to orthodontic force and moved mesially.Three weeks later,the force was removed,and the teeth relapsed.The rats of experimental group were received local injections of odanacatib.The control group received saline instead.Tooth movement and relapse were measured when appliances removed after 0 day and 2 weeks.The rats were sacrificed after the 2-week relapse.The microcomputed tomography analysis was performed to quantify the alveolar bone,and the values of bone mineral density(BMD) and bone volume fraction(BVF) were measured.The percentage of relapse in the experimental group was significantly lower than that in the control group(P <0.05),and the BMD and BVF of alveolar bone in the experimental group were significantly higher than those in the control group(P <0.05).Local injection of odanacatib effectively inhibit the relapse after orthodontic tooth movement in rats.
3.Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients
Xiaoxia KOU ; Yongmei DING ; Yao HUANG ; Zhengang YUAN ; Qijun QIAN
Journal of Pharmaceutical Practice 2015;(3):258-260,268
Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory Tcells (Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive im-munotherapy .Methods 32 patients were enrolled in this study from January 2012 to October 2014 ,among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy (gemcitabine group) ,the other 16 patients received adoptive immunotherapy only(control group) .The level of Tregs in peripheral blood ,side effect and overall survival were observed be-fore and after the therapy .Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy ,and it was also lower than that of the control group .The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10 .0 mo vs 8 .7 mo) .Conclusion Therapeutic regimen of gemcitabine can remarkly de-plete Tregs in peripheral blood of patients with pancreatic cancer ,effectively regulate tumor immune tolerance ,and improve the efficacy of adoptive immunotherapy .
4.Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor
Yong XIA ; Xiaoxia KOU ; Xijing YANG ; Fuping ZHOU ; Qian ZHANG ; Qijun QIAN
Journal of Pharmaceutical Practice 2017;35(2):174-177
Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer .Methods From October 2015 to March 2016 ,18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital .Clinical efficacy ,adverse reactions and progression free survival time were monitored .The quality of life were compared before and after the treatment .Results Among 18 cases , PR 5 cases ,SD 7 cases and PD 6 cases .The KPS scores for quality of life was significantly increased (P<0 .05) after treat-ment .At the end of follow-up ,5 patients died ,2 patients were lost in follow-up ,11 patients survived .The median progression free survival was 2 .6 months (95% CI:1 .8-3 .3 months) .No serious adverse reactions and abnormal laboratory results were reported .Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors .It is well tolerated and has less ad-verse reactions .The randomized control studies with larger samples are needed to further confirm our conclusions .